Drug policy reform advocates are asking a key congressional committee to reject a Republican lawmaker’s attempt to block Washington, D.C. from enacting an initiative to decriminalize certain psychedelics.
Rep. Andy Harris (R-MD)—who has also championed provisions preventing D.C. from implementing legal marijuana sales after local voters passed a cannabis initiative in 2014—signaled last week that he’s planning to introduce an amendment to a spending bill during a committee meeting on Wednesday that would restrict the District from allowing the psychedelics measure to be implemented even if it is approved by voters in November.
The Drug Policy Alliance (DPA) is in favor of the proposal and, on Tuesday, it sent a letter to leadership in the House Appropriations Committee asking members to oppose Harris’s amendment and any other effort to restrict the democratic process for D.C. residents.
The measure, which hasn’t formally qualified for the ballot yet but received significantly more signatures than required when activists submitted them last week, would make a wide range of entheogenic substances including psilocybin mushrooms and ayahuasca among the jurisdiction’s lowest law enforcement priorities. However, it wouldn’t technically change local statute.